FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
Doctors share everything to know about the buzzy treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results